medwireNews

1 week ago | medwirenews.com | Lynda Williams |Lucy Piper

By Lynda Williams, medwireNews ReportermedwireNews: For patients with active cancer and venous thromboembolism, a reduced dose of apixaban is noninferior to the standard dose for preventing recurrent thromboembolic episodes and significantly reduces the risk of clinically relevant bleeding, report the API-CAT investigators. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

2 weeks ago | medwirenews.com | Lynda Williams |Lucy Piper

By Lynda Williams, medwireNews ReportermedwireNews: Children who survive for at least 5 years after treatment for cancer are 2.7 times more likely to develop one of eight aging-related chronic health conditions before the age of 65 years than members of the general population, US researchers suggest. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

3 weeks ago | medwirenews.com | Lynda Williams |Lucy Piper

By Lynda Williams, medwireNews ReportermedwireNews: Research indicates that women with triple-negative breast cancer might benefit from low-dose tamoxifen to reduce the risk of recurrent or new primary disease. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. Read the full story on the L’Institut Servier websiteImage credit: © Crystal light / Stock.adobe.com

1 month ago | medwirenews.com | Lucy Piper

By Lucy Piper, medwireNews ReportermedwireNews: Tetramethylpyrazine nitrone does not slow overall functional decline in patients with amyotrophic lateral sclerosis, but it may help retain grip strength and is well tolerated, suggest study findings. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. Read the full story on the L’Institut Servier websiteImage credit: © JuanCi Studio / stock.adobe.com

1 month ago | medwirenews.com | Lynda Williams |Lucy Piper

By Lynda Williams, medwireNews ReportermedwireNews: The presence of two or more high-risk chromosomal aberrations in patients with multiple myeloma is associated with an especially poor outcome throughout the disease course, shows research published in the Journal of Clinical Oncology. This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France. Read the full story on the L’Institut Servier websiteImage credit: © luchschenF / stock.adobe.com